STN heads into the aftermath of its Q1 2026 results with a sharp week-long selloff, a record backlog, and short sellers quietly doubling their positions over the past month.
The stock fell 9.1% over the past five sessions to CAD 114.25 — a notably steeper decline than closest TSX peer WSP, which held roughly flat on the week, and ATRL, which actually gained 2.4%. US engineering peer ACM was also hit hard, dropping 8.2%, suggesting broader sector pressure in the week. But STN's underperformance relative to Canadian peers stands out: the selloff arrived ahead of Q1 numbers, and the results, released after close on May 13, tell a mixed story. Adjusted EPS of $0.97 beat the $0.95 consensus estimate. Revenue of $1.235 billion missed $1.260 billion. Management affirmed full-year adjusted EPS guidance of $4.37–$4.49 against a $4.47 Street estimate, and full-year sales guidance of $5.054–$5.194 billion below consensus at $5.220 billion. The headline was a record backlog of $9.0 billion and adjusted EPS growth of 14.7%.
Short positioning tells a more cautious story than usual, even if it remains modest in absolute terms. Short interest doubled from roughly 1.3% of the free float in mid-April to 2.2% now — a 67% jump over 30 days. The step-change happened in two distinct moves: a jump in late April that took shares from 1.46 million to 2.25 million, and a further move in early May to 2.48 million. That 10% weekly increase keeps short interest at the elevated end of its recent range. Yet borrow remains cheap and widely available. Cost to borrow has eased sharply from a peak above 3% in mid-April to just 0.54% — a 54% drop over the month. Availability is extremely loose: with only 0.44% of the lending pool currently in use, well below the 52-week peak of 1.69%, there is no meaningful squeeze pressure. Bears can build positions without paying up. The ORTEX short score of 32.9 is near the bottom half of the range, consistent with rising but still light short interest rather than any extreme bear conviction.
The Street appears constructive but has been trimming expectations. The mean analyst price target of CAD 164 implies roughly 43% upside from current levels — though the most recent analyst data is approximately 15 days old, just past the threshold for freshness, so individual moves should be treated as indicative rather than current. Factor scores paint a mixed picture: the dividend score ranks in the 90th percentile, reflecting Stantec's well-established payout history. EV/EBITDA has compressed to 11.5x over the past 30 days as the price has fallen, while the PE multiple of 17.8x is down about 1.3 turns over the same period. EPS momentum is neutral at 44 (30-day) and 56 (90-day), and EPS surprise ranks only in the 35th percentile — the Q1 beat on EPS was slim.
Insider activity deserves a brief mention. Net buying over the past 90 days totals about $598,000 across multiple executives. The largest single trades came from a divisional COO (3,400 shares at CAD 88.75) and an EVP (1,250 shares at CAD 88.92), both on March 16, when the stock had been under pressure. Board members made smaller routine purchases in early April at around CAD 122. None of these are especially large in dollar terms, but the consistent direction — all buys, no sales across ten separate transactions — reflects management conviction at lower price levels than where the stock now trades.
What to watch next is whether the Q1 miss on revenue and the below-consensus full-year sales guidance prompt analyst price target cuts, and whether the record backlog of $9 billion is enough to keep the institutional holder base — which includes Vanguard, Mackenzie, and several large Canadian managers — steady at current weightings.
See the live data behind this article on ORTEX.
Open STN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
